A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma

Inclusion Criteria: * Signed Informed Consent Form * Age ≥ 18 years * Documented ovarian, primary peritoneal, or fallopian tube carcinoma that has recurred * No prior chemotherapy in the recurrent setting * Measurable disease * Recovered from prior radiation therapy or surgery Exclusion Criteria: * Prior chemotherapy treatment for recurrent ovarian, primary peritoneal, or fallopian tube carcinoma * History of abdominal fistula, gastrointestinal perforation (GIP), or intra-abdominal abscess * Patients with clinical symptoms or signs of gastrointestinal (GI) obstruction or who require parenteral hydration, parenteral nutrition, or tube feeding * Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure * Current, recent, or planned participation in an experimental drug study * History of systemic bevacizumab (Avastin) or other vascular endothelial growth factor (VEGF) or VEGF receptor-targeted agent use * Inadequately controlled hypertension * Prior history of hypertensive crisis or hypertensive encephalopathy * New York Heart Association Class II or greater congestive heart failure (CHF) * History of myocardial infarction or unstable angina * History of stroke or transient ischemic attack (TIA) * Known central nervous system (CNS) disease except for treated brain metastasis * Significant vascular disease or recent peripheral arterial thrombosis * History of hemoptysis * Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)